During the The Western Vascular Society 2006 Annual Meeting, Angiotech Pharmaceuticals Inc. (ANPI) presented the results of a preclinilal study showing the efficacy of its Vascular Wrap™ paclitaxel-eluting mesh and Lifespan® graft technology platform.
Results demonstrated that neointimal hyperplasia was reduced by a minimum of 87.6% in animals who received a paclitaxel-eluting mesh compared with animals who received no mesh.
"We are encouraged by the results of our preclinical data, and believe that we may be able to offer a better treatment option for hemodialysis patients," said Dr. Rui Avelar, Chief Medical Officer of Angiotech Pharmaceuticals.
"These results, complemented by the extensive experience with paclitaxel in cardiovascular applications, have given us further confidence as we look to start our clinical studies in hemodialysis access."
Angiotech will launch a clinical trial in the UK this fall to determine if hemodialysis patients who receive the Vascular Wrap paclitaxel-eluting mesh/Lifespan graft combination product experience fewer graft failures than those patients that receive the graft alone.
A similar trial is also planned in the US. Details of the study methods and results are further described in Angiotech's press release.
Comment Preview